Simon P M, Neethling F A, Taniguchi S, Goode P L, Zopf D, Hancock W W, Cooper D K
Neose Technologies, Inc., Horsham, Pennsylvania 19044, USA.
Transplantation. 1998 Feb 15;65(3):346-53. doi: 10.1097/00007890-199802150-00009.
Hyperacute rejection (HAR) of pig-to-primate discordant xenografts is caused by the deposition of preexisting natural antibodies that recognize Galalpha1-3Gal (alphaGal)-terminating oligosaccharides on glycoproteins and glycolipids, followed by complement-mediated lysis of the graft's endothelium. In vitro, these natural xenoantibodies can be blocked by alphaGal-containing oligosaccharides. We undertook in vivo pig-to-baboon cardiac xenotransplantation experiments to evaluate free oligosaccharides as inhibitors of HAR.
Initial 15-min intravenous infusions of alphaGal-oligosaccharides into baboons were used to measure pharmacokinetic parameters, and to assess the extent of neutralization of anti-alphaGal antibody activity. AlphaGal trisaccharide (Galalpha1-3Galbeta1-4GlcNAc) or pentasaccharide (Galalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc ) was administered at 0.5 mmol/kg into baboons. Next, two baboons that received porcine heterotopic heart xenografts were continuously infused with alphaGal pentasaccharide for 4-5 hr, maintaining the serum oligosaccharide concentration in the millimolar range.
Pharmacokinetic analysis indicated that the oligosaccharides were rapidly cleared from the blood, with a serum half-life of 50 min. In the period during which blood oligosaccharide concentration was above 1 mM, as determined by high-pressure liquid chromatography, the serum cytotoxic activity against porcine cells was completely abolished. HAR of the xenograft was inhibited during the infusions, although there was some histological and immunohistological evidence of antibody-mediated injury on biopsies taken at the end of this period.
Intravenous alphaGal oligosaccharides, by inhibiting anti-alphaGal antibody activity, delay but do not abolish the onset of HAR.
猪到灵长类动物不匹配异种移植物的超急性排斥反应(HAR)是由预先存在的天然抗体沉积引起的,这些抗体识别糖蛋白和糖脂上以Galα1-3Gal(αGal)结尾的寡糖,随后补体介导移植物内皮细胞的裂解。在体外,这些天然异种抗体可被含αGal的寡糖阻断。我们进行了猪到狒狒的心脏异种移植体内实验,以评估游离寡糖作为HAR抑制剂的效果。
对狒狒进行最初15分钟的αGal-寡糖静脉输注,以测量药代动力学参数,并评估抗αGal抗体活性的中和程度。将αGal三糖(Galα1-3Galβ1-4GlcNAc)或五糖(Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc)以0.5 mmol/kg的剂量给予狒狒。接下来,对两只接受猪异位心脏异种移植的狒狒持续输注αGal五糖4 - 5小时,将血清寡糖浓度维持在毫摩尔范围内。
药代动力学分析表明,寡糖从血液中迅速清除,血清半衰期为50分钟。通过高压液相色谱测定,在血液寡糖浓度高于1 mM的时间段内,针对猪细胞的血清细胞毒性活性完全消失。在输注期间,异种移植物的HAR受到抑制,尽管在此期间结束时所取活检组织有一些组织学和免疫组织学证据表明存在抗体介导的损伤。
静脉注射αGal寡糖通过抑制抗αGal抗体活性,延迟但不能消除HAR的发生。